The European Patients' Academy on Therapeutic Innovation (EUPATI) IMI project resulted in a number of key outputs for the field of patient engagement. The core activities continue running until 2019 under a PPP consortium under an EPF programme focusing on the Patient Expert Training Course, the multilingual public Toolbox, and the EUPATI National Platforms Network. It is imperative that these pillars that support the patient engagement landscape exist in the medium- and long-term to address the growing field of patient engagement. Further investment is needed to develop sustainable models of collaboration to ensure this, and put into place the infrastructure required for these to work, building on those already established under IMI-EUPATI.

The PharmaLedger project will create a blockchain-based framework for the efficient digitization of the healthcare industry. The goal of the project is to provide a widely trusted platform that will support the design and adoption of blockchain-enabled healthcare solutions while accelerating delivery of innovation that will benefit the entire ecosystem, from manufacturers to patients. PharmaLedger will serve as a single source of truth for the healthcare ecosystem and will be designed for efficient decentralized governance, wide adoption by the stakeholders of the ecosystem, compliance with extant and emerging standards and regulation, and end-to-end connectivity and interoperability. Sustainability of the platform will be ensured by leveraging existing, successful blockchain technologies; open source reference implementation; and a fully documented, actionable methodology for evolutionary digitization of the healthcare industry. The project will address the key challenges of the healthcare ecosystem through prioritized delivery of applications and validation of business use cases, including but not be limited to end-to-end product tracking for combating counterfeit medicines and medical supplies; supply chain integrity; efficiency of recruitment and submission in clinical trials; and machine-learning health data marketplaces. The platform will support integrated use of medical devices across the use cases. The PharmaLedger project brings together 28 partners from 10 EU Member States, including 11 large pharmaceutical companies; highly innovative technology SMEs specializing in blockchain development, security, privacy and business intelligence; universities and research institutes specializing in pharmacoeconomic analysis, research of patient requirements, big data analytics and electronic health records; leading clinical trials companies; supply chain partners; patient representatives; and leading healthcare service providers.

ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about the safety of medication use in pregnancy and lactation. What do we deliver? ConcePTION aims to create a paradigm shift in how we study medication safety in pregnancy. We will establish (1) a successful, sustainable open-science based EU non-proprietary ecosystem of public and private stakeholders, pregnant women and researchers to generate and disseminate timely and reliable evidence on drugs across maternal, neonatal and long term outcomes of medication exposure in pregnancy and breastfeeding (2) a catalogue with fully characterized data sources for rapid selection of suitable data sources; 3) operational, business, network, information and data governance models, (4) quality assured and tested methodological approaches, analytical tools and data platforms allowing for distributed analyses, (5) procedures and tools for collection of digital data and samples directly from pregnant women, (6) In vitro, in silico and in vivo models for prediction of drug transfer in human milk, (7) a biobank and analytical network for quantification of drug in human milk, (8) best practice documents endorsed by regulators and health authorities and (9) a web-based drug information knowledge bank. How do we deliver? (1) Experienced leaders, able to manage challenging networks and public-public or public-private partnerships. (2) Defragmentation by connecting all key stakeholders and EU networks in this area. (3) Re-use of data, tools and foreground from prior European commission funded projects. (4) Connecting to leaders of similar initiatives in the USA, Canada, Asia and other parts of the world. (5) Systematic consensus & endorsement building. (6) Quality throughout as a precondition to trust the results and information by all users.